Resonac Holdings Corporation
Notice Regarding Revision of Full-Year Consolidated Earnings Forecast
Revision of full-year consolidated earnings forecast. Revenue is expected to decrease from the previous forecast of 1,310,000 million yen to 1,165,000 million yen, while core operating income is expected to rise from 140,000 million yen to 196,000 million yen. The Crystallase Chemical segment is treated as a non-continuing business, and overall revenue is expected to decrease, though some segments are anticipated to contribute to profit.
Key Figures
- Revenue: 1,165,000 million yen
- Core operating income: 196,000 million yen
- Net income for the period: 112,500 million yen
AI要約
Overview of performance
In this release, the full-year consolidated earnings forecast for the fiscal year ending December 2026 is revised downward to revenue of 1,165,000 million yen, while core operating income is expected to increase to 196,000 million yen. Major factors from the previous forecast include the treatment of the Crystallase Chemical segment as a non-continuing business, resulting in revenue decline, and higher profit from increased sales volume in the semiconductor/electronics materials segment. The impact of discontinuation of consolidation is not included.
Outlook and implications
Excluding the impact of non-continuing operations, core indicators are expected to rise. However, due to the treatment change of the Crystallase Chemical segment, total revenue is expected to decrease. External factors such as exchange rates may continue to affect performance, so close attention to future updates is required.
Publicly listed company: Resonac Holdings Corporation
Company overview · Stock price · Financial data · All IR
